Boston Scientific Corp. (BSX: Quote) Sunday reported clinical endpoint data from the Platinum workhorse clinical trial comparing the safety and effectiveness of the Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent System to the Cobalt Chromium Xience V Everolimus-Eluting Coronary Stent System.
At three years, the Promus Element Stent continued to demonstrate advantages over the Xience V Stent, the company said.
Around the world, approximately four million people with cardiovascular disease are treated each year with stents used to help keep vessels open. Stents, which are placed and expanded to fit the size, shape and bend of the artery, may also be coated with a drug.
Click here to receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News